< Back to situations

Get alerts on this situation

We’ll email you as it develops, and you can follow the whole thread from day one.

Unsubscribe anytime.

[SITUATION] · [ACTIVE]

4 clusters · 10 sources · 23 days · First seen 24 days ago · Last updated 1 day ago

Categories: HEALTH

Serbia‑Russia mRNA cancer vaccine partnership

Entities: Aleksandr Ginzburg · Oncopept · Alexandr Ginzburg · Neooncovac · mRNA anti‑tumor vaccine

Overview

In early July 2026 a Serbian delegation led by Minister without Portfolio Nenad Popović met Russian health officials in Moscow to lay the groundwork for Serbian access to Russia’s personalized mRNA cancer vaccine, NEOONKOVAK. By late July the collaboration moved to clinical use: a Serbian patient was scheduled for treatment and Russia formally approved the vaccine for adult patients with inoperable or metastatic melanoma on 28 July, marking the world’s first approval of an mRNA anti‑tumor vaccine.

On 30 July 2026 Russian scientists reported that the first dose administered to a 60‑year‑old man with stage III melanoma and metastases produced a strong immune response that exceeded expectations. The Gamaleya Research Institute plans to prepare vaccines for ten additional patients within one and a half to three months, aiming to treat up to 20 melanoma patients by year‑end. Researchers are also extending the personalized‑vaccine platform to pancreatic, kidney and small‑cell lung cancers.

These developments keep the partnership on track, with Serbia positioned to benefit from Russia’s expanding clinical programme and forthcoming manufacturing capacity.

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

[● 4 SOURCES] Russia's Ministry of Health approved the mRNA vaccine Neooncovac for advanced melanoma and the peptide drug Oncopept for colorectal cancer last year. (Regulatory approval)
[● 4 SOURCES] The first patient treated with Neooncovac is a 60‑year‑old man with stage III melanoma and metastases. (Patient details)
[● 4 SOURCES] Neooncovac is produced individually for each patient using tumour and healthy tissue genetic analysis to create a custom mRNA vaccine. (Vaccine production method)
[● 4 SOURCES] The institute plans to prepare personalized vaccines for ten more patients, with production completed within 1.5 to 3 months. (Future production plan)
[● 3 SOURCES] The patient felt normal and showed a very positive immune response after vaccination. (Clinical observation)
[● 3 SOURCES] Aleksandr Ginzburg said the immune response exceeded expectations. (Scientific director statement)
[● 2 SOURCES] Gamaleya Institute is also developing personalized vaccines for pancreatic, kidney and small‑cell lung cancers. (Research pipeline)
[○ 1 SOURCE] A total of up to 20 patients are expected to receive the vaccine by the end of the year. (Year‑end target)

Timeline

1 day ago

[HEALTH] 5 sources
Russia's personalized melanoma vaccine Neooncovac shows promising early results
Russia’s Gamaleya Institute gave the first patient a personalized melanoma mRNA vaccine, Neooncovac, reporting good health and a strong immune response; plans target 20 patients by year‑end.
4 days ago

[HEALTH] 2 sources
Russia approves first mRNA vaccine for melanoma treatment
Russia has granted the first approval for an mRNA vaccine targeting melanoma, a personalized therapy that still requires extensive clinical validation.
6 days ago

[HEALTH] 2 sources
Serbian Patient Set to Begin Russian Personalized Cancer Vaccine Therapy
A Serbian patient will begin treatment with a Russian personalized mRNA cancer vaccine in August, the first case outside Russia, following limited early success in two Russian patients.
24 days ago

[HEALTH] 2 sources
Serbian delegation pursues Russian personalized mRNA cancer vaccine for patients
Serbian minister Nenad Popović led a Moscow delegation to negotiate access to Russia’s new personalized mRNA cancer vaccine, aiming to treat Serbian patients both abroad and later at home.

Sources

anlatilaninotesi.com.tr · expres.mk · infokuryr.cz · kks.ch · kurir.rs · nin.rs · novamakedonija.com.mk · politika.rs · rtk.co.rs · zoom.mk

This summary has been updated 3 times: see revision history